Larimar Therapeutics (LRMR) Operating Expenses (2013 - 2025)

Larimar Therapeutics' Operating Expenses history runs 13 years deep, the most recent figure standing at $64.0 million for Q4 2025.

• Quarterly Operating Expenses rose 104.58% year-over-year to $64.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $172.5 million (up 89.79% YoY) and the FY2025 annual result came in at $172.5 million, up 89.79% from the prior year.
• Operating Expenses was $64.0 million for Q4 2025 at Larimar Therapeutics, up from $49.5 million in the prior quarter.
• Across five years, Operating Expenses topped out at $64.0 million in Q4 2025 and bottomed at $7.6 million in Q1 2023.
• A 5-year average of $19.6 million and a median of $13.4 million in 2021 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2022 — Operating Expenses slumped 49.12% — and 2025, when it soared 171.02%.
• Larimar Therapeutics' Operating Expenses stood at $9.1 million in 2021, then climbed by 14.89% to $10.4 million in 2022, then jumped by 35.66% to $14.2 million in 2023, then soared by 120.96% to $31.3 million in 2024, then surged by 104.58% to $64.0 million in 2025.
• Business Quant data shows LRMR's Operating Expenses at $64.0 million in Q4 2025, $49.5 million in Q3 2025, and $27.8 million in Q2 2025.